NEW YORK, November 2 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced that at its adjourned Annual General Meeting held yesterday, all the resolutions proposed to the shareholders were approved.
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges .
Contact: Ron Bentsur, Chief Executive Officer Tel: +1-212-531-5960
XTL Biopharmaceuticals Ltd
CONTACT: Contact: Ron Bentsur, Chief Executive Officer, Tel:+1-212-531-5960
